359 related articles for article (PubMed ID: 9616372)
1. Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.
Gorczynski RM; Chen Z; Zeng H; Gorczynski L; Terzioglu E
Immunology; 1998 Feb; 93(2):221-9. PubMed ID: 9616372
[TBL] [Abstract][Full Text] [Related]
2. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
3. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
[TBL] [Abstract][Full Text] [Related]
4. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
[TBL] [Abstract][Full Text] [Related]
5. A subset of gamma delta T-cell receptor-positive cells produce T-helper type-2 cytokines and regulate mouse skin graft rejection following portal venous pretransplant preimmunization.
Gorczynski RM; Chen Z; Hoang Y; Rossi-Bergman B
Immunology; 1996 Mar; 87(3):381-9. PubMed ID: 8778022
[TBL] [Abstract][Full Text] [Related]
6. Gamma delta TCR+ hybridomas derived from mice preimmunized via the portal vein adoptively transfer increased skin allograft survival in vivo.
Gorczynski RM; Cohen Z; Leung Y; Chen Z
J Immunol; 1996 Jul; 157(2):574-81. PubMed ID: 8752904
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of lymphoid tissues under the influence of a subclinical level of graft versus host reaction induced by bone marrow T cells or splenic T cell subsets.
Hirano M; Arase H; Arase-Fukushi N; Ogasawara K; Iwabuchi K; Miyazaki T; Good RA; Onoé K
Cell Immunol; 1993 Oct; 151(1):118-32. PubMed ID: 8402923
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression induced by hepatic portal venous immunization spares reactivity in IL-4 producing T lymphocytes.
Gorczynski RM
Immunol Lett; 1992 Jun; 33(1):67-77. PubMed ID: 1427992
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.
Blazar BR; Taylor PA; Smith S; Vallera DA
Blood; 1995 Feb; 85(3):842-51. PubMed ID: 7833486
[TBL] [Abstract][Full Text] [Related]
11. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
13. Intestinal graft versus native liver cytokine expression in a rat model of intestinal transplantation with and without donor-specific cell augmentation.
Levay-Young B; Gruessner SE; Shearer JD; Cheol Kim S; Nahkleh RE; Gruessner RW
J Surg Res; 2003 Sep; 114(1):78-89. PubMed ID: 13678702
[TBL] [Abstract][Full Text] [Related]
14. Approach to withdrawal from tacrolimus in a fully allogeneic murine skin graft model.
Uchiyama H; Kong Y; Kishihara K; Sugimachi K; Nomoto K
Immunology; 1999 Jun; 97(2):294-300. PubMed ID: 10447745
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR
J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888
[TBL] [Abstract][Full Text] [Related]
16. Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.
Xu K; Li C; Pan X; Du B
Int J Hematol; 2007 Jul; 86(1):84-90. PubMed ID: 17675273
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of rejection of small intestinal and skin allografts in rats by injection of antibodies to ICAM-1 or the integrins alpha 4, alpha L, or beta 2.
Gorczynski RM; Fu XM; Issekutz T; Cohen Z
Cell Immunol; 1998 Feb; 184(1):74-82. PubMed ID: 9626338
[TBL] [Abstract][Full Text] [Related]
18. Influence of graft versus host reaction on the T cell repertoire differentiating from bone marrow precursors following allogeneic bone marrow transplantation.
Onoé K; Arase N; Arase H; Takayanagi T; Nishihori H; Iwabuchi K; Ogasawara K; Good RA
Transpl Immunol; 1997 Jun; 5(2):75-82. PubMed ID: 9269028
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model.
Chen BJ; Chen Y; Cui X; Fidler JM; Chao NJ
Transplantation; 2002 Jan; 73(1):115-21. PubMed ID: 11792990
[TBL] [Abstract][Full Text] [Related]
20. Intermediate TCR cells can induce graft-versus-host disease after allogeneic bone marrow transplantation.
Weerasinghe A; Kawamura T; Moroda T; Seki S; Watanabe H; Abo T
Cell Immunol; 1998 Apr; 185(1):14-29. PubMed ID: 9636679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
